Literature DB >> 12766554

Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.

Kazuo Mihara1, Tsuyoshi Kondo, Norio Yasui-Furukori, Akihito Suzuki, Masayuki Ishida, Shingo Ono, Takahiro Kubota, Tatsuji Iga, Yutaka Takarada, Ronald de Vries, Sunao Kaneko.   

Abstract

The effects of various CYP2D6 genotypes on the steady-state plasma concentrations (Css) of risperidone and its active metabolite, 9-hydroxyrisperidone, were studied in 85 Japanese schizophrenic patients (27 men and 58 women) treated with 6 mg/d risperidone for at least 2 weeks. Plasma concentrations of risperidone and 9-hydroxyrisperidone were measured using liquid chromatography-tandem mass spectrometry. The patients had the following CYP2D6 genotypes: wild-type (wt)/wt (40 patients), CYP2D6*10 (*10)/wt ( 28), CYP2D6*5 (*5)/wt ( 8), *10/*10 ( 5), *5/*10 ( 3), and CYP2D6*4/CYP2D6*14 ( 1), respectively. The Css values of risperidone and 9-hydroxyrisperidone were corrected to the median body weight of 58 kg. The medians (ranges) of the Css of risperidone in the aforementioned genotype groups were 2.2 (0.37-35.7), 6.4 (2.1-26.5), 12.3 (4.7-39.5), 19.4 (13.4-26.4), 64.0 (41.6-68.8), and 91.8 nmol/L. Those values for risperidone-to-9-hydroxyrisperidone ratio were 0.03 (0.01-0.33), 0.06 (0.03-0.19), 0.14 (0.07-0.29), 0.28 (0.25-0.38), 0.48 (0.38-0.58), and 2.35, respectively. The Css of risperidone was significantly (P < 0.05 or P < 0.001) different among the four genotype groups (wt/wt, *10/wt, *5/wt, and *10/*10), except between the *5/wt and *10/*10 groups. Also, the risperidone-to-9-hydroxyrisperidone ratio significantly (P < 0.005 or P < 0.001) differed among these genotype groups. No significant differences were found in the Css of 9-hydroxyrisperidone and the active moiety (the Css of risperidone plus 9-hydroxyrisperidone) among these genotype groups. This study confirms previous findings that the CYP2D6 status affects the Css of risperidone via its strong regulation of 9-hydroxylation of risperidone. However, similar active moiety of risperidone among different genotype groups suggests that the determination of the CYP2D6 genotype has little importance for clinical situations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12766554     DOI: 10.1097/00007691-200306000-00006

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  9 in total

1.  Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.

Authors:  Lisa Alina Kneller; Francisco Abad-Santos; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2020-01       Impact factor: 6.447

2.  Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.

Authors:  Frederik Vandenberghe; Monia Guidi; Eva Choong; Armin von Gunten; Philippe Conus; Chantal Csajka; Chin B Eap
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

3.  Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.

Authors:  Norio Yasui-Furukori; Kazuo Mihara; Takenori Takahata; Akihito Suzuki; Taku Nakagami; Ronald De Vries; Tomonori Tateishi; Tsuyoshi Kondo; Sunao Kaneko
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

Review 4.  Pharmacogenomics can improve antipsychotic treatment in schizophrenia.

Authors:  Qingqing Xu; Xi Wu; Yuyu Xiong; Qinghe Xing; Lin He; Shengying Qin
Journal:  Front Med       Date:  2013-04-21       Impact factor: 4.592

5.  Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome.

Authors:  Daiji Kato; Chiaki Kawanishi; Ikuko Kishida; Taku Furuno; Kyoko Suzuki; Hideki Onishi; Yoshio Hirayasu
Journal:  Eur J Clin Pharmacol       Date:  2007-08-14       Impact factor: 2.953

6.  A Prospective Study to Evaluate the Effect of CYP2D6 Polymorphism on Plasma level of Risperidone and its Metabolite in North Indian Patients with Schizophrenia.

Authors:  Bir S Chavan; Gurjit Kaur; Deepti Gupta; Jitender Aneja
Journal:  Indian J Psychol Med       Date:  2018 Jul-Aug

7.  Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone.

Authors:  Jinjun Lu; Ye Yang; Jian Lu; Zuqing Wang; Yiping He; Yeliang Yan; Kai Fu; Wenjuan Jiang; Yunqing Xu; Renrong Wu; Wenqing Liu; Jingping Zhao
Journal:  BMC Psychiatry       Date:  2021-02-03       Impact factor: 3.630

8.  CYP2D6 Genetic Variation and Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis.

Authors:  Yanisa Wannasuphoprasit; Stig Ejdrup Andersen; Maria J Arranz; Rosa Catalan; Gesche Jurgens; Sanne Maartje Kloosterboer; Henrik Berg Rasmussen; Anjali Bhat; Haritz Irizar; Dora Koller; Renato Polimanti; Baihan Wang; Eirini Zartaloudi; Isabelle Austin-Zimmerman; Elvira Bramon
Journal:  Front Psychol       Date:  2022-02-03

9.  Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.

Authors:  John K Darby; David J Pasta; Michael G Wilson; John Herbert
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 3.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.